These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37386139)

  • 121. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule.
    Engel P; Zhou LJ; Ord DC; Sato S; Koller B; Tedder TF
    Immunity; 1995 Jul; 3(1):39-50. PubMed ID: 7542548
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.
    Mayordomo JI; Zorina T; Storkus WJ; Zitvogel L; Celluzzi C; Falo LD; Melief CJ; Ildstad ST; Kast WM; Deleo AB
    Nat Med; 1995 Dec; 1(12):1297-302. PubMed ID: 7489412
    [TBL] [Abstract][Full Text] [Related]  

  • 123. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.
    Li N; Geng S; Dong ZZ; Jin Y; Ying H; Li HW; Shi L
    Mol Cancer; 2024 Jun; 23(1):117. PubMed ID: 38824567
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Macrophage based drug delivery: Key challenges and strategies.
    Guo Q; Qian ZM
    Bioact Mater; 2024 Aug; 38():55-72. PubMed ID: 38699242
    [TBL] [Abstract][Full Text] [Related]  

  • 125. CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy.
    Huang J; Yang Q; Wang W; Huang J
    Front Immunol; 2024; 15():1378739. PubMed ID: 38665921
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
    Yuan G; Ye M; Zhang Y; Zeng X
    Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy.
    Yang S; Wang Y; Jia J; Fang Y; Yang Y; Yuan W; Hu J
    Cell Death Dis; 2024 Apr; 15(4):238. PubMed ID: 38561367
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.
    Liang Y; Xu Q; Gao Q
    Front Immunol; 2023; 14():1291619. PubMed ID: 38090576
    [TBL] [Abstract][Full Text] [Related]  

  • 129. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.
    Dong X; Fan J; Xie W; Wu X; Wei J; He Z; Wang W; Wang X; Shen P; Bei Y
    Br J Cancer; 2023 Aug; 129(3):551-562. PubMed ID: 37386139
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
    Qian S; Chen J; Zhao Y; Zhu X; Dai D; Qin L; Hong J; Xu Y; Yang Z; Li Y; Guijo I; Jiménez-Galanes S; Guadalajara H; García-Arranz M; García-Olmo D; Shen J; Villarejo-Campos P; Qian C
    Cytotherapy; 2024 Feb; 26(2):113-125. PubMed ID: 37999667
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 133. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
    Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
    J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.
    Song Y; Tong C; Wang Y; Gao Y; Dai H; Guo Y; Zhao X; Wang Y; Wang Z; Han W; Chen L
    Protein Cell; 2018 Oct; 9(10):867-878. PubMed ID: 28284008
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
    Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
    Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
    [TBL] [Abstract][Full Text] [Related]  

  • 136.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.